Table 2 Seropositivity and negativity for Anti-HCV and HBsAg in PHC and health blood donors
From: Seroprevalence of HBV and HCV in primary hepatocellular carcinoma patients in Zimbabwe
Parameter | PHC (n = 60) | Control s (n = 30) | p value |
|---|---|---|---|
Anti-HCV positivity | 12 (20%) | 0 (0%) | <0.05 |
Anti-HCV negativity | 48 (80% | 30 (100%) | <0.05 |
HBsAg positivity | 29 (48.3%) | 4 (13.3%) | <0.05 |
HBsAg negativity | 31 (51.7%) | 26 (86.7%) | <0.05 |
Dual anti-HCV & HBsAg positivity | 5 (8.3%) | 0 (0%) | - |
Anti-HCV and/or HBsAg positivity | 36 (60%) | 4 (13.3%) | - |
Anti-HCV and/or HBsAg negativity | 24 (40%) | 26 (86.7%) | - |